Q-omics provides the consensus-scored ICAM3 profile across patient tissues and cancer cell-line models. ICAM3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ICAM3 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ICAM3 protein abundance shows 26,639 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ICAM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ICAM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ICAM3 survival associations across molecular data types. ICAM3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ICAM3 RNA expression–survival associations across cancer types. High ICAM3 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, LUAD, BRCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ICAM3 RNA expression.
This table summarizes ICAM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ICAM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ICAM3 shows lower tumor expression in COAD, LUSC, KICH and UCEC and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher ICAM3 RNA expression in tumor versus normal tissue (log2 FC = +1.305, t-test p < 0.001).
This table shows molecular features associated with ICAM3 in patient tissues and cancer cell lines. In patient samples, ICAM3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ICAM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
